⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19917034 | 0.80 | ADORA1 (0.31) | — | |
| SCHEMBL7624796 | 0.80 | PDK2 (0.35) | — | |
| SCHEMBL12963989 | 0.79 | YTHDC1 (0.37) | — | |
| SCHEMBL13267125 | 0.77 | KDM4E (0.39) | — | |
| SCHEMBL14026293 | 0.77 | — | — | |
| SCHEMBL16174576 | 0.68 | — | — | |
| SCHEMBL9797840 | 0.67 | ADORA3 (0.41) | — | |
| SCHEMBL7807974 | 0.65 | — | — | |
| SCHEMBL18621022 | 0.64 | PRMT5 (0.40) | — | |
| SCHEMBL11509283 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-12-14 | — | — | US | disclosed |
| US-11673879-B2 | Substituted pyrimidines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673879-B2 | Substituted pyrimidines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-06-13 | — | — | US | disclosed |
| WO-2023007185-A1 | IMIDAZOLE ORGANIC COMPOUNDS AND THEIR USE AGAINST INFLAMMATORY BOWEL DISEASE | Benevolentai Cambridge Limited (GB) | 2023-02-02 | — | — | WO | disclosed |
| WO-2020108619-A1 | MNK INHIBITOR | 上海迪诺医药科技有限公司 | 2020-06-04 | — | — | WO | disclosed |
| US-20120178767-A1 | TREATMENT OF LIVER DISORDERS WITH P13K INHIBITORS | GILEAD CALISTOGA LLC (US) | 2012-07-12 | — | — | US | disclosed |
| WO-2010120987-A1 | RING FUSED, UREIDOARYL- AND CARBAMOYLARYL-BRIDGED MORPHOLINO-PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH LLC (US) | 2010-10-21 | — | — | WO | disclosed |
| US-20100216820-A1 | THIENOPYRIMIDIONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS | ICOS CORPORATION | 2010-08-26 | — | — | US | disclosed |
| US-20100069408-A1 | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition | ASTRAZENECA AB (SE) | 2010-03-18 | — | — | US | disclosed |
| US-20080214812-A1 | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | disclosed |
| US-20070265282-A1 | Use of ticagrelor treating myocardial infarction, thrombotic stroke, angina and transient ischemic attacks | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | US | disclosed |
| US-7250419-B2 | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition | ASTRAZENECA AB (SE) | 2007-07-31 | — | — | US | disclosed |